«Lenalidomide maintenance
following autologous stem cell transplant can now be considered a standard of care for people with multiple myeloma,» says Dr. McCarthy, senior author on the meta - analysis and Principal Investigator of the U.S. study, CALGB (Alliance) 100104.
For this analysis, 605 patients with newly diagnosed multiple myeloma and treated with continuous lenalidomide (brand name Revlimid)
following autologous stem cell transplant were compared to 604 patients who were treated with placebo or no maintenance.
Not exact matches
Journal reference: JAMA, C - Peptide Levels and Insulin Independence
Following Autologous Nonmyeloablative Hematopoietic
Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
As Dr. Maharaj explained, «One last option for Gale was high dose chemotherapy
followed by an
autologous bone marrow
stem cell transplant.